$RMTG

Regenerative Medical Technology Group Inc.

CIK:0001760026|SEC Filings

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
Revenue	$ 4,022,763	$ 983,318	$ 6,662,116	$ 2,347,859
Cost of revenue	1,444,592	397,686	2,317,454	818,133
Gross profit	2,578,171	585,632	4,344,662	1,529,726
Operating expenses
Advertising and marketing	546,603	147,605	937,650	304,926
Professional Fee	708,117	363,533	1,236,272	695,266
Officer compensation	22,500	22,500	45,000	45,000
Depreciation and amortization expense	90,810	54,832	188,504	106,646
Investor relations	25,000	40,000	46,500	40,000
General and administrative	619,164	207,449	1,094,976	453,015
Total operating expenses	2,012,194	835,919	3,548,902	1,644,853
Income (loss) from operations	565,977	(250,087)	795,760	(115,127)
Other income (expense)
Interest expense	(2,233,797)	(1,055,371)	(4,140,730)	(1,949,221)
Change in derivative liabilities	(1,237,653)	(138,119)	129,045	(139,268)
Total other expense	(3,471,450)	(1,193,490)	(4,011,685)	(2,088,489)
Net loss	$ (2,905,473)	$ (1,443,577)	$ (3,215,925)	$ (2,203,616)
Basic and diluted earnings (loss) per share from:
Net loss per common share, basic	$ (0.22)	$ (0.12)	$ (0.24)	$ (0.18)
Net loss per common share, diluted	$ (0.22)	$ (0.12)	$ (0.18)	$ (0.24)
Weighted average number of common shares outstanding, basic (in Shares)	13,224,682	12,538,968	13,182,062	12,538,968
Weighted average number of common shares outstanding, diluted (in Shares)	13,224,682	12,538,968	13,182,062	12,538,968

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (3,215,925)	$ (2,203,616)
Non-cash adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Amortization of debt discount	1,075,041	57,864
Depreciation and amortization expense	188,504	106,646
Changes in the fair value of derivative liability	(129,045)	139,268
Preferred shares issued with debt		401
Changes in operating assets and liabilities:
Accounts receivable	(66,429)	(14,071)
Prepaid expenses	(307,012)	(105,179)
Inventory	(321,891)	(95,573)
Other asset	(10,000)
Accounts payable and accrued liabilities	3,220,855	1,573,276
CASH PROVIDED (USED) BY OPERATING ACTIVITIES	434,098	(540,984)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment	(358,893)	(110,582)
CASH USED BY INVESTING ACTIVITIES	(358,893)	(110,582)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of debt	291,381	1,100,000
CASH PROVIDED BY FINANCING ACTIVITIES	291,381	1,100,000
Net increase in cash	366,586	448,434
Cash, beginning of period	956,718	1,165,820
Cash, end of period	1,323,304	1,614,254
Cash paid for income taxes
Cash paid for interest
NON-CASH FINANCING ACTIVITIES
Discount issued on debt	58,957
Preferred series CC shares issued on debt		401,248
Common shares issued for conversion of note	9,120
Warrants discount issued on debt	$ 212,500	$ 400,847

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2026	Dec. 31, 2025
Current assets
Cash and cash equivalents	$ 1,323,304	$ 956,718
Accounts receivable	110,244	43,815
Inventory	481,168	159,277
Prepaid expenses	369,962	62,950
Total current assets	2,284,678	1,222,760
Property and equipment, net	1,089,917	870,759
Other assets	145,365	32,538
Intangible assets, net	12,694	61,464
Right of use asset, net	637,370	621,195
Goodwill	1,679,978	1,679,978
Total assets	5,850,003	4,488,694
Current liabilities
Accounts payable and accrued liabilities	81,351	348,394
Accrued interest	19,615,846	16,559,277
Customer advances	431,936	351,193
Derivative liability	3,236,010	3,049,719
Lease liability, current portion	157,681	219,973
Convertible notes payable, net	2,147,452	2,147,452
Notes payable, net	16,935,021	15,444,488
Total current liabilities	42,613,096	38,128,296
Long term liabilities
Lease liability, net of current portion	492,425	409,110
Notes payable, net of current portion	1,999,999	1,999,999
Total liabilities	45,105,519	40,537,405
Commitments and contingencies (Note 7)
Stockholders’ deficit
Common stock, $0.001 par value: 100,000,000 shares authorized: 13,738,968 and 13,138,968 issued and outstanding as of June 30, 2026, and December 31, 2025, respectively	13,739	13,139
Additional paid in capital	40,213,949	40,205,429
Accumulated deficit	(79,484,265)	(76,268,340)
Total stockholders’ deficit	(39,255,516)	(36,048,711)
Total liabilities and stockholders’ deficit	5,850,003	4,488,694
Related Party
Current liabilities
Notes payable-related parties	7,800	7,800
Series AA Preferred Stock
Stockholders’ deficit
Preferred stock, value	1,050	1,050
Series CC Preferred Stock
Stockholders’ deficit
Preferred stock, value	1	1
Series DD Preferred Stock
Stockholders’ deficit
Preferred stock, value	$ 10	$ 10